source
- CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trialCG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
- Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with SanofiSeawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…